Company Encyclopedia
View More
name
Kaneka Corporation
4118.JP
News
View More

06:30 ET Polyhydroxyalkanoate (PHA) Market worth $265.2 million by 2030 - Exclusive Report by MarketsandMarkets™

The Polyhydroxyalkanoate (PHA) market is projected to grow from USD 123.8 million in 2025 to USD 265.2 million by 2030, at a CAGR of 16.5%. The growth is driven by rising demand in packaging, food services, biomedical, and agriculture applications. Europe dominated the market in 2024, with North America as the second-largest market. Key players include Teknor Apex, Kaneka Corporation, and Ecomann Biotechnology. The market is expanding due to the increasing focus on sustainability and biodegradable materials.

prnewswire·
4118
0.00%
prnewswire·
4118
0.00%

12:18 ET Kaneka Nutrients Expands Market Surveillance Efforts in Next Release of Ubiquinol Authenticity Testing

Kaneka Nutrients is enhancing its efforts to ensure the authenticity of Ubiquinol products due to concerns about misleading label claims. The company is conducting expanded market surveillance and laboratory testing in collaboration with Kaneka Corporation and third-party labs. This initiative aims to provide reliable information for consumers and industry partners, ensuring product quality and safety. Kaneka Nutrients emphasizes the importance of transparency and accountability in the supplement industry and encourages verification of product authenticity through the Kaneka Quality Seal.

prnewswire·
4118
0.00%
prnewswire·
4118
0.00%

Kaneka Acquires Zeon’s Gastrointestinal and Cardiovascular Medical Device Businesses

Kaneka Corporation has agreed to acquire Zeon Corporation's medical device businesses in the gastrointestinal and cardiovascular sectors, operated by Zeon Medical Inc. and River Xemex Co., Ltd. This acquisition will position Kaneka as the third-largest player in the domestic gastrointestinal market, particularly in endoscopic treatment devices. The agreement, signed on November 12, 2025, aims to enhance Kaneka's product portfolio and improve patient quality of life.

Reuters·
4118
0.00%
4205
0.00%
Reuters·
4118
0.00%
4205
0.00%

Kaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026

Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.

marketscreener·
4118
0.00%
marketscreener·
4118
0.00%

Kaneka Expands Global Reach with i-ED COIL Launch in Europe

Kaneka Corporation has launched its i-ED COIL, a brain aneurysm embolization coil, in Europe as of October, following EC certification in July. The product offers enhanced flexibility for treating irregularly shaped aneurysms and is expected to reduce rupture risks. Since its 2019 launch in Japan, sales have grown steadily. Kaneka aims to expand its medical device business and achieve JPY 300 billion in sales by 2030 in the Health Care Solution Unit.

marketscreener·
4118
0.00%
marketscreener·
4118
0.00%
© 2025 Longbridge｜Disclaimer